Precigen Secures FDA Approval for PAPZIMEOS, First RRP Treatment
- Precigen's PAPZIMEOS is the first FDA-approved treatment for recurrent respiratory papillomatosis (RRP) in adults.
- The company's rapid commercialization efforts reflect strong demand and growing patient interest in PAPZIMEOS.
- Precigen is prepared for increased demand, ensuring efficient access to PAPZIMEOS through established manufacturing and supply chain capabilities.
Precigen Achieves Milestone with FDA Approval of PAPZIMEOS for RRP Treatment
Precigen, Inc. has reached a pivotal milestone with the FDA's approval of PAPZIMEOS (zopapogene imadenovec-drba), marking it as the first and only treatment specifically designed for adults with recurrent respiratory papillomatosis (RRP). This breakthrough therapy addresses a significant unmet medical need for individuals suffering from this debilitating condition. The company quickly moves forward with the commercialization process, reflecting strong demand as prescriptions fill nationwide. Since November, the number of patients enrolled in the PAPZIMEOS patient hub has doubled, indicating a robust interest from both major medical centers and community practices eager to provide this innovative solution to their patients.
The expansion of access to PAPZIMEOS plays a critical role in its market penetration. Currently, private health plans cover the therapy for approximately 170 million lives, which includes major insurers alongside Medicare and Medicaid. This broad acceptance is crucial for ensuring that patients can effectively access this life-changing treatment. Helen Sabzevari, PhD, President and CEO of Precigen, highlights the rapid adoption of PAPZIMEOS, driven by compelling safety and efficacy data. The strong engagement from healthcare providers further underscores the therapy’s potential to redefine treatment protocols for RRP, which has long posed challenges to patients and clinicians alike.
Phil Tennant, Chief Commercial Officer at Precigen, underscores the company’s preparedness to meet the growing demand for PAPZIMEOS, citing established manufacturing and supply chain capabilities. Engagement efforts across targeted healthcare centers are nearing completion, reinforcing the company’s commitment to ensuring that the therapy reaches patients efficiently. With current capital resources positioned to support operations until the company achieves cash flow break-even, Precigen is well-poised for continued growth and expansion. The anticipated global availability of PAPZIMEOS, following the validation of its Marketing Authorization Application by the European Medicines Agency, further solidifies the therapy's significance in the global healthcare landscape.
In addition to its promising therapy, Precigen plans to present at the upcoming 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. This event will serve as a platform to showcase the company’s advancements in innovative precision medicines, reinforcing its commitment to transforming patient care.
As Precigen navigates this exciting phase of growth, the company remains focused on fulfilling its mission to provide groundbreaking treatments that address critical health challenges, ultimately enhancing the quality of life for patients suffering from RRP and potentially other conditions in the future.
